Therma Bright Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Roberto Fia
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1173 Dundas Street East Toronto ON Canada M4M 3P1
- IPO Date
- Jan 8, 2021
- Website
- thermabright.com
- Similar Companies
- Business
- Therma Bright Inc. is a Canada-based developer and partner specializing in advanced proprietary diagnostic and medical device technologies focused on respiratory diseases, vascular health, and consumer medical devices. Founded and headquartered in Toronto, Ontario, the company’s core product portfolio includes the Venowave circulation booster for blood clot prevention and vascular health; AcuVid COVID-19 rapid antigen and antibody diagnostic tests; InterceptCS cold sore prevention system; TherOZap insect bite therapy device; and Benepod hot-and-cold pain therapy device. Additional technologies under development include the PREVA™ clot retriever device for ischemic stroke treatment through the subsidiary Inretio, digital cough test Ai4lyf, inhaled statin therapy InStatin, and other innovative healthcare solutions marketed under brands such as TheroZap, AcuVid, and InterceptCS. Recent major developments include an expanded strategic partnership with Gen-X Med for U.S. distribution of Venowave targeting the specialized knee surgery market segment, along with the receipt of a permanent Healthcare Common Procedure Coding System (HCPCS) code for Venowave enhancing reimbursement pathways. In 2024-2025, Therma Bright completed a strategic review resulting in the planned spin-off of its consumer product portfolio into a separate publicly traded entity, expanded U.S. marketing and distribution agreements with Global Wellness Products for cold sore and pain therapy devices, and amended warrant exercise pricing from private placements to improve capital structure. The company also successfully advanced clinical and pharmacokinetic studies for its inhaled statin therapy InStatin and achieved regulatory and commercialization milestones for its PREVA™ clot retriever device. These operational expansions fortify Therma Bright’s position across diagnostic, therapeutic, and consumer medical device markets with a focus on innovation in medical technology. Therma Bright serves consumer, institutional, and healthcare professional markets primarily within Canada and the United States. Its integrated product offerings address critical healthcare challenges including circulatory improvement, respiratory diagnostics, pain management, inflammation reduction, and vascular interventions through a combination of thermal therapy, advanced diagnostics, and medical devices. The company continues to invest in research and development partnerships, clinical trials, and commercial alliances to broaden its proprietary medical technology platform and accelerate market penetration. This comprehensive approach positions Therma Bright as a developing leader in diagnostic and therapeutic medical devices with a diversified portfolio spanning consumer health solutions and cutting-edge medical technologies in vascular and respiratory care sectors.
Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets
Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually
Therma Bright Grants Stock Options
Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial
Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales
Therma Bright Proposes to Amend Certain Warrants
Therma Bright Announces Share Consolidation
Therma Bright Inc. Announces Share Consolidation
Therma Bright Proposes to Amend Certain Warrants and Negotiates Debt Settlements
Therma Bright Inc. Provides Update on InStatin Development, Announcement of Key Strategic Advisor and Highlights Preclinical and IP Progress at InStatin
Therma Bright Secures New Customer Initial Purchase Order, Signaling Market Confidence
Therma Bright Reviews Manufacturing Strategy in Light of US Tariff Changes
Therma Bright Secures an Initial Limited Exclusive U.S. Marketing and Distribution Contract for Its Consumer Products with Global Wellness Products LLC
Therma Bright Welcomes Healthcare and Technology Expert Steve Raysely to its Advisory Board
Therma Bright Secures Purchase Order For 1,750 Venowave W5 Units From National Distributor - DME Authority of Nashville, TN
Therma Bright Secures Purchase Order For Initial 100 Venowave Units From New National Distribution Partner - Valor Medical of San Antonio
Therma Bright Announces Shares for Debt Issuance